Report of the Pathology Committee: False-positive and false-negative diagnoses of prostate cancer

BJU International, Supplement

Volumn 92, Issue 2, 2003, Pages 62-65

  Van Der Kwast, T H ^a,h   Lopes, C ^b   Martikainen, P M ^c   Pihl, C G ^d   Santonja, C ^e   Neetens, I ^f   Lollo, S D I ^g   Hoedemaeker, R F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^f MIDDELHEIM HOSPITAL   (Belgium)

^g UNIVERSITY OF FLORENCE   (Italy)

^h JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

False negative diagnosis; False positive diagnosis; Pathology; Prostate cancer; Screening

Indexed keywords

DNA;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ERROR; DNA DETERMINATION; HUMAN; HYPERPLASIA; LABORATORY DIAGNOSIS; MALE; NEEDLE BIOPSY; NOMENCLATURE; PATHOLOGIST; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; DIAGNOSTIC ERRORS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0346495989     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54
2. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 1192-8
3. De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268-73
4. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997; 21: 1489-95
5. Van der Kwast TH, Lopes C, Santonja C et al. and Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003; 56: 336-40
6. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol 1996; 20: 851-7
7. Kronz JD, Milord R, Wilentz R, Weir EG, Schreiner SR, Epstein JI. Lesions missed on prostate biopsies in cases sent in for consultation. Prostate 2003; 54: 310-4
8. Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores, another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol 1998; 22: 440-5
9. Vis AN, Hoedemaeker RF, Roobol M, Schroder FH, van der Kwast TH. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer. Cancer 2001; 92: 524-34
10. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-10
11. Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intra-epithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69; an autopsy study of 249 cases. In Vivo 1994; 8: 439-43
12. Hoedemaeker RF, Boeken Kruger AE, Van der Kwast TH. How many biopsies should be taken for proper diagnosis and grading? Progress and Controversies in Oncological Urology V. Renal, Bladder and Prostote Cancer, an Update. The Parthenon Publishing Group Inc., 1998: 109-30
13. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158: 1886-90
14. Murphy WM. The current status of the pathology of prostate cancer. Cancer Control 1998; 5: 500-6
15. Vis AN, Kranse R, Roobol M, van der Kwast TH, Schroder FH. Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 2002; 89: 384-9